

Zhenfeng Duan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1089463/zhenfeng-duan-publications-by-citations.pdf>
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139 papers	5,098 citations	38 h-index	64 g-index
143 ext. papers	5,996 ext. citations	6.5 avg, IF	5.78 L-index

#	Paper	IF	Citations
139	Interleukin-6 signaling pathway in targeted therapy for cancer. <i>Cancer Treatment Reviews</i> , 2012 , 38, 904-104	11.4	475
138	Recent advances in synthesis and surface modification of lanthanide-doped upconversion nanoparticles for biomedical applications. <i>Biotechnology Advances</i> , 2012 , 30, 1551-61	17.8	260
137	MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1337-45	6.1	211
136	Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 5055-63	12.9	204
135	Distance-dependent plasmon-enhanced fluorescence of upconversion nanoparticles using polyelectrolyte multilayers as tunable spacers. <i>Scientific Reports</i> , 2015 , 5, 7779	4.9	144
134	Programmed cell death ligand 1 expression in osteosarcoma. <i>Cancer Immunology Research</i> , 2014 , 2, 690-698	6.8	135
133	Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 833-8	6.1	115
132	Exosomes promote pre-metastatic niche formation in ovarian cancer. <i>Molecular Cancer</i> , 2019 , 18, 124	42.1	106
131	Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. <i>Clinical Cancer Research</i> , 2003 , 9, 2778-85	12.9	94
130	Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. <i>Oncotarget</i> , 2017 , 8, 84559-84571	3.3	93
129	Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 5759-69	12.9	77
128	Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. <i>Journal of Orthopaedic Research</i> , 2010 , 28, 746-52	3.8	72
127	Advances in immune checkpoint inhibitors for bone sarcoma therapy. <i>Journal of Bone Oncology</i> , 2019 , 15, 100221	4.5	69
126	TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. <i>Gene</i> , 1999 , 229, 75-81	3.8	68
125	Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2122-30	6.1	67
124	SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. <i>Clinical Cancer Research</i> , 2006 , 12, 6844-52	12.9	64
123	Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 55, 277-85	3.5	64

122	CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 681-9	3.5	62
121	Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. <i>PLoS ONE</i> , 2014 , 9, e101283	3.7	60
120	High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. <i>Cancer</i> , 2012 , 118, 2905-14	6.4	58
119	CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. <i>Scientific Reports</i> , 2015 , 5, 11365	4.9	55
118	Synthesis of upconversion NaYF ₄ :Yb ³⁺ ,Er ³⁺ particles with enhanced luminescent intensity through control of morphology and phase. <i>Journal of Materials Chemistry C</i> , 2014 , 2, 3671-3676	7.1	54
117	Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016 , 1866, 266-275	11.2	54
116	Role of microRNA-1 in human cancer and its therapeutic potentials. <i>BioMed Research International</i> , 2014 , 2014, 428371	3	51
115	Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. <i>Clinical Cancer Research</i> , 2012 , 18, 4580-8	12.9	51
114	MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET. <i>Tumor Biology</i> , 2015 , 36, 6715-23	2.9	50
113	Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. <i>Journal of Orthopaedic Research</i> , 2015 , 33, 199-207	3.8	50
112	Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. <i>Cancer Letters</i> , 2010 , 293, 220-9	9.9	50
111	Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. <i>BMC Cancer</i> , 2010 , 10, 187	4.8	49
110	Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. <i>International Journal of Cancer</i> , 2019 , 145, 979-993	7.5	48
109	Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. <i>Molecular Medicine Reports</i> , 2016 , 14, 4042-4048	2.9	47
108	Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. <i>EBioMedicine</i> , 2019 , 39, 182-193	8.8	47
107	RNA sequencing (RNA-Seq) and its application in ovarian cancer. <i>Gynecologic Oncology</i> , 2019 , 152, 194-201	4.1	47
106	Rhabdomyosarcoma: Advances in Molecular and Cellular Biology. <i>Sarcoma</i> , 2015 , 2015, 232010	3.1	45
105	Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. <i>Oncotarget</i> , 2016 , 7, 38333-38346	3.3	44

104	GBP1 overexpression is associated with a paclitaxel resistance phenotype. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 25-33	3.5	42
103	Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. <i>Cancer Letters</i> , 2014 , 342, 104-12	9.9	41
102	Regulation of microRNAs function by circular RNAs in human cancer. <i>Oncotarget</i> , 2017 , 8, 64622-64637	3.3	40
101	MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. <i>Journal of Orthopaedic Research</i> , 2014 , 32, 1075-82	3.8	38
100	NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. <i>PLoS ONE</i> , 2009 , 4, e7415	3.7	37
99	miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo. <i>Molecular Oncology</i> , 2017 , 11, 151-166	7.9	36
98	Therapeutic applications of histone deacetylase inhibitors in sarcoma. <i>Cancer Treatment Reviews</i> , 2017 , 59, 33-45	14.4	36
97	Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth. <i>Scientific Reports</i> , 2015 , 5, 10433	4.9	36
96	The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer. <i>Oncotarget</i> , 2016 , 7, 40846-40859	3.3	36
95	Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 3113-21	8.3	35
94	8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. <i>Molecular Pharmacology</i> , 2007 , 72, 1137-45	4.3	34
93	Near-infrared light activated delivery platform for cancer therapy. <i>Advances in Colloid and Interface Science</i> , 2015 , 226, 123-37	14.3	33
92	Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. <i>Journal of Orthopaedic Research</i> , 2014 , 32, 695-701	3.8	33
91	Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. <i>Spine</i> , 2010 , 35, 1668-75	3.3	33
90	Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. <i>Scientific Reports</i> , 2016 , 6, 25239	4.9	33
89	Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications. <i>Cancer Treatment Reviews</i> , 2020 , 82, 101934	14.4	32
88	miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint. <i>Experimental Cell Research</i> , 2019 , 380, 20-28	4.2	31
87	Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma. <i>PLoS ONE</i> , 2013 , 8, e75851	3.7	31

86	From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma. <i>Cancer and Metastasis Reviews</i> , 2018 , 37, 719-731	9.6	31
85	Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. <i>Cancer Letters</i> , 2020 , 474, 158-167	9.9	30
84	MicroRNA-155 expression is independently predictive of outcome in chordoma. <i>Oncotarget</i> , 2015 , 6, 9125-39	3.3	30
83	Expression and Therapeutic Potential of SOX9 in Chordoma. <i>Clinical Cancer Research</i> , 2017 , 23, 5176-5186	6.9	29
82	Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer. <i>FASEB Journal</i> , 2019 , 33, 5990-6000	0.9	29
81	MicroRNA-7 regulates IL-1 β -induced extracellular matrix degeneration by targeting GDF5 in human nucleus pulposus cells. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 83, 1414-1421	7.5	29
80	Establishment and characterization of a novel chordoma cell line: CH22. <i>Journal of Orthopaedic Research</i> , 2012 , 30, 1666-73	3.8	29
79	Regulation of microRNA-1 (miR-1) expression in human cancer. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2017 , 1860, 227-232	6	28
78	The roles and implications of exosomes in sarcoma. <i>Cancer and Metastasis Reviews</i> , 2016 , 35, 377-90	9.6	26
77	p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 349-56	3.5	26
76	An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 107	22.4	26
75	Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2377-85	6.1	26
74	Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosis. <i>Cellular Oncology (Dordrecht)</i> , 2017 , 40, 209-218	7.2	25
73	Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 1573-1582	6.9	25
72	Application of liquid biopsy in bone and soft tissue sarcomas: Present and future. <i>Cancer Letters</i> , 2018 , 439, 66-77	9.9	25
71	Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma. <i>Cancer Letters</i> , 2016 , 373, 109-118	9.9	24
70	Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	24
69	Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells. <i>International Journal of Nanomedicine</i> , 2015 , 10, 2913-24	7.3	24

68	Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1691-701	6.1	24
67	NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. <i>British Journal of Pharmacology</i> , 2016 , 173, 613-26	8.6	23
66	The role of extracellular matrix in osteosarcoma progression and metastasis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 178	12.8	23
65	Selective enhancement of red emission from upconversion nanoparticles via surface plasmon-coupled emission. <i>RSC Advances</i> , 2015 , 5, 76825-76835	3.7	22
64	Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920922055	5.4	22
63	The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma. <i>Cancer and Metastasis Reviews</i> , 2016 , 35, 151-63	9.6	22
62	CSPG4 as a prognostic biomarker in chordoma. <i>Spine Journal</i> , 2016 , 16, 722-7	4	21
61	CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells. <i>Cellular Physiology and Biochemistry</i> , 2018 , 46, 1218-1230	3.9	20
60	Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. <i>International Journal of Cancer</i> , 2015 , 137, 2029-39	7.5	20
59	Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications. <i>Cancer Treatment Reviews</i> , 2018 , 63, 61-70	14.4	19
58	Three-dimensional (3D) culture in sarcoma research and the clinical significance. <i>Biofabrication</i> , 2017 , 9, 032003	10.5	19
57	The Roles of Sox Family Genes in Sarcoma. <i>Current Drug Targets</i> , 2016 , 17, 1761-1772	3	19
56	PTEN in osteosarcoma: Recent advances and the therapeutic potential. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020 , 1874, 188405	11.2	19
55	Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. <i>Hepatology Research</i> , 2019 , 49, 1097-1108	5.1	18
54	Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2018 , 150, 143-150	4.9	18
53	Targeting protein kinases to reverse multidrug resistance in sarcoma. <i>Cancer Treatment Reviews</i> , 2016 , 43, 8-18	14.4	18
52	Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007 , 450, 187-94	5.1	18
51	Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2019 , 37, 789-798	3.8	17

50	Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. <i>Cell Death and Disease</i> , 2018 , 9, 446	9.8	16
49	Aberrant DNA methylations in chondrosarcoma. <i>Epigenomics</i> , 2016 , 8, 1519-1525	4.4	16
48	Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. <i>PLoS ONE</i> , 2014 , 9, e93996	3.7	16
47	A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. <i>BMC Cancer</i> , 2014 , 14, 681	4.8	16
46	Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 1121-9	3.5	16
45	Autophagy as a potential target for sarcoma treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017 , 1868, 40-50	11.2	15
44	Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application. <i>Cancer Letters</i> , 2020 , 479, 54-60	9.9	14
43	Clinical and biological significance of PIM1 kinase in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2016 , 34, 1185-94	3.8	13
42	Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential. <i>OncImmunology</i> , 2014 , 3, e954467	7.2	13
41	ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines. <i>PLoS ONE</i> , 2009 , 4, e6967	3.7	13
40	RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 607-14	3.5	13
39	CDK4 expression in chordoma: A potential therapeutic target. <i>Journal of Orthopaedic Research</i> , 2018 , 36, 1581-1589	3.8	13
38	Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma. <i>Scientific Reports</i> , 2017 , 7, 1580	4.9	12
37	Nanoparticles: a promising modality in the treatment of sarcomas. <i>Pharmaceutical Research</i> , 2011 , 28, 260-72	4.5	12
36	MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. <i>Gene</i> , 2004 , 340, 53-9	3.8	12
35	Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats. <i>Scientific Reports</i> , 2016 , 6, 25659	4.9	11
34	Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray. <i>Journal of Orthopaedic Research</i> , 2016 , 34, 1606-12	3.8	11
33	Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2020 , 38, 1952-1964	3.8	10

32	NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. <i>Gynecologic Oncology</i> , 2015 , 137, 134-42	4.9	9
31	An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein. <i>Current Cancer Drug Targets</i> , 2018 , 18, 677-696	2.8	9
30	Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma. <i>Journal of Orthopaedic Research</i> , 2019 , 37, 510-521	3.8	9
29	Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. <i>Scientific Reports</i> , 2017 , 7, 43941	4.9	8
28	Application of metabolomics in sarcoma: From biomarkers to therapeutic targets. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 116, 1-10	7	8
27	Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells. <i>Oncotarget</i> , 2018 , 9, 13154-13166	3.3	8
26	The emerging roles and therapeutic potential of microRNAs (miRs) in liposarcoma. <i>Discovery Medicine</i> , 2015 , 20, 311-24	2.5	8
25	In vitro effects of mitomycin C on the proliferation of the non-small-cell lung cancer line A549. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 20516-23		7
24	Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation. <i>Cancer Letters</i> , 2021 , 505, 37-48	9.9	7
23	Transcriptional activation of CBF β by CDK11 is necessary to promote osteosarcoma cell proliferation. <i>Cell Communication and Signaling</i> , 2019 , 17, 125	7.5	6
22	Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920956900	5.4	6
21	ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920982853	5.4	5
20	Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067. <i>Journal of Cancer</i> , 2020 , 11, 132-141	4.5	5
19	T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma. <i>Cell Proliferation</i> , 2020 , 53, e12901	7.9	5
18	Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2020 , 38, 2362-2372	3.8	5
17	Expression and Clinical Implication of Autophagy-Associated Protein p62 in Osteosarcoma. <i>Oncology</i> , 2018 , 95, 52-60	3.6	4
16	cDNA Technologies and their application to drug resistance research: power, potential and problems. <i>Drug Resistance Updates</i> , 2000 , 3, 277-282	23.2	4
15	Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777. <i>Journal of Orthopaedic Research</i> , 2020 , 38, 902-910	3.8	4

14	Aberration of Promoter Methylation in Chondrosarcoma. <i>Anticancer Research</i> , 2017 , 37, 2939-2945	2.3	3
13	SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma.. <i>Bioscience Reports</i> , 2022 ,	4.1	2
12	regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer.. <i>Annals of Translational Medicine</i> , 2022 , 10, 203	3.2	2
11	Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value. <i>European Spine Journal</i> , 2020 , 29, 3214-3228	2.7	1
10	T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma. <i>Molecular Oncology</i> , 2021 , 15, 3721-3737	7.9	1
9	Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X21995069	3.8	1
8	Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study. <i>Frontiers in Oncology</i> , 2020 , 10, 596330	5.3	0
7	Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 644857	5.3	0
6	Crystallization and characterization of small molecular multidrug resistance inhibitor targeting P-glycoprotein, NSC23925 isomers. <i>Journal of Molecular Structure</i> , 2019 , 1193, 7-13	3.4	
5	High miR-3609 expression is associated with better prognosis in TNBC based on mining using systematic integrated public sequencing data.. <i>Experimental and Therapeutic Medicine</i> , 2022 , 23, 54	2.1	
4	Advances in the Molecular Biology of Chondrosarcoma 2021 , 27-52		
3	Long noncoding RNA and bone sarcoma 2022 , 471-485		
2	Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma.. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 149, 112888	7.5	
1	ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.. <i>American Journal of Cancer Research</i> , 2022 , 12, 1577-1592	4.4	